1026575-13-2

Upstream product

• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 189365-91-1 tert-butyl 2-[(3S)-4-(2-[(benzyloxycarbonyl)amino]acetyl)-3-[[(tert-butoxycarbonyl)amino]methyl]-2-oxopiperazinyl]acetate 
• 356535-16-5 benzyl (2S)-2-[[(tert-butoxycarbonyl)amino]methyl]-4-[2-(tert-butoxy)-2-oxoethyl]-3-oxo-3,4-dihydro-1(2H)-pyrazinecarboxylate 
• 1026483-30-6 [3-(tert-butoxycarbonylamino-methyl)-2-oxo-piperazin-1-yl]-acetic acid tert-butyl ester 
• 356535-20-1 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid 
• 356535-26-7 methyl (Z)-4-(2-amino-2-(hydroxyimino)ethyl)benzoate 

Relevant academic research and scientific papers

Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: Synthesis and pharmacological evaluation of 2-oxopiperazine derivatives

A series of 2-oxopiperazine derivatives, possessing basic moieties at the 3- and the 4-positions, were synthesized and evaluated for their abilities to inhibit platelet aggregation and for their effects on bleeding time. Among the compounds, 2-[(3S)-4-[2-[(4-guanidinobenzoyl)amino] acetyl]3-[3-[(4-guanidinobenzoyl)amino]propyl]-2-oxopiperazinyl]acetic acid (12c) showed a potent inhibitory effect on platelet aggregation and good dissociation between the efficacy and the bleeding side effect. Intravenous infusion of compound 12c at 1.6 μg/mL/min. completely prevented arterial thrombus formation induced by endothelial injury in guinea pigs. The dose of 12c that prolonged the bleeding time to three times the control value was 5.8/μg/mL/min. These results suggest that compound 12c might be useful in the clinical treatment of thrombotic diseases, and we selected 12c (TAK-024) as a candidate for the clinical trials.